Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This open-label phase II trial studies how well olaparib in combination with pembrolizumab
works in treating patients with advanced, metastatic melanoma with the homologous
recombination (HR) pathway gene mutation / alteration. Olaparib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth, and potentially augment an
anti-tumor immune response to pembrolizumab. The trial is designed to assess the efficacy and
safety of olaparib in combination with pembrolizumab in patients with HR mutation/ alteration
whose disease progressed on prior immunotherapy and/or BRAF-targeting therapy
Phase:
Phase 2
Details
Lead Sponsor:
California Pacific Medical Center Research Institute